Morning Breakouts

Latest KFF Health News Stories

The Health Law’s Unlikely Defenders: Republicans

Morning Briefing

As Republican efforts to dismantle and replace the Affordable Care Act continue, some in the party are speaking out for provisions in the legislation, such as coverage for people with pre-existing conditions. Meanwhile, a left-leaning group will launch attack ads just in time for congressional recess, media outlets look at the ramifications of the GOP health plan and what’s next for the resistance movement that helped bring about the collapse of the Republicans’ bill.

Cities, States Seeking To Break Crime Cycles Look At New Mental Health Options For Prisoners

Morning Briefing

“If you took drugs and alcohol and mental illness out of my jail, my jail would be empty,” Sheriff Mark Wasylyshyn of Wood County, Ohio, tells Stateline. Also, a federal judge in New York says state officials are subverting a court order to help mentally ill residents, and a new mental health program for teens is launched in Palo Alto, Calif.

Maryland Is First State To Take Steps To Protect Planned Parenthood Funding

Morning Briefing

The measure would direct $2 million from Maryland’s Medicaid budget and $700,000 for the state’s general fund to family-planning services. Meanwhile, California becomes latest state to support Planned Parenthood of Ohio in its suit against a state law excluding abortion providers from participating in publicly funded programs, and Shonda Rhimes joins the board of the organization.

FDA’s Process Dinged For Being ‘Burdensome And Slow,’ But It’s Faster Than Its European Counterpart

Morning Briefing

Dr. Scott Gottlieb, President Donald Trump’s pick to head the Food and Drug Administration, has been focused on what he’ll do to speed up the drug approval process to make it more like Europe. But the FDA is actually faster already. Meanwhile, a Medicare advisory panel backs a plan that could save $5 billion over five years in drug costs. And taxpayers fund pharmaceutical research but then have to pay exorbitant prices on those drugs — but if the U.S. government doesn’t do it, no one will.